Rebiotix: Ferring Pharmaceuticals: Ferring and Rebiotix Present Landmark Phase 3 Data Demonstrating Superior Efficacy of Investigational RBX2660 Versus Placebo to Reduce Recurrence of C. difficile Infection
RBX2660 pivotal Phase 3 trial successfully met the primary endpoint; data presented today at Digestive Disease Week (DDW) RBX2660 is the first microbiota-based live biotherapeutic to demonstrate e...
Read full article »
Rebiotix is a biotechnology company that develops microbiota restoration therapies for the treatment of gastrointestinal diseases.
Read more